Harmony BioSciences’ shares fall following critical short-seller report


A short-seller raised questions about the company's narcolepsy drug; Harmony "disagrees with their assertions."

Previous Program from Secret wants to help Gen Z, millennial women stop sweating their finances
Next Santa Clara Valley Medical Center doctors to be led by new management